Mainz Biomed B.V.
MYNZ · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.2% | -28.3% | 142.5% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -108.2% | 68.6% | 61.3% | 18.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,700.7% | -2,702.8% | -1,818.7% | -5,872% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,910.3% | -2,847.4% | -2,116.8% | -2,413.5% |
| EPS Diluted | -2.65 | -7.71 | -19.73 | -11.73 |
| % Growth | 65.6% | 60.9% | -68.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |